

July 13, 2018

**VIA EDGAR**

U.S. Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Washington, D.C. 20549

Attn: Mary Beth Breslin  
Jeffrey Gabor

**Re: Rubius Therapeutics, Inc. (the "Company")  
Registration Statement on Form S-1  
File No. 333-225840**

**Acceleration Request**

**Requested Date: July 17, 2018**

**Requested Time: 4:00 p.m. Eastern Standard Time**

Ladies and gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended (the "**Act**"), J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Jefferies LLC and Leerink Partners LLC, as representatives of the several underwriters, hereby join Rubius Therapeutics, Inc. in requesting that the Securities and Exchange Commission take appropriate action to cause the Registration Statement on Form S-1 (File No. 333-225840) (the "**Registration Statement**") to become effective on Tuesday, July 17, 2018, at 4:00 p.m., Eastern Standard Time, or as soon as practicable thereafter.

Pursuant to Rule 460 under the Act, please be advised that we will take reasonable steps to secure adequate distribution of the preliminary prospectus, to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement.

We have been informed by the participating underwriters that they will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, to the extent applicable.

*[Signature Page Follows]*

---

Very truly yours,

As representatives of the several underwriters

**J.P. MORGAN SECURITIES LLC**

By: /s/ David Ke  
Name: David Ke  
Title: Managing Director

**MORGAN STANLEY & CO. LLC**

By: /s/ Kalli Dircks  
Name: Kalli Dircks  
Title: Executive Director

**JEFFERIES LLC**

By: /s/ Matthew Kim  
Name: Matthew Kim  
Title: Managing Director

**LEERINK PARTNERS LLC**

By: /s/ Stuart R. Nayman  
Name: Stuart R. Nayman  
Title: Managing Director, Senior Legal Counsel

